Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension.

Abstract

In one study of 10 patients with mild-to-moderate hypertension, equivalent total daily doses (13 +/- 2 mg) of isradipine given twice daily and a modified-release formulation of isradipine (isradipine MR) given once daily were found to control adequately 24 h ambulatory blood pressure compared with placebo (P less than .001 for each v placebo). In another study of 22 patients with essential hypertension, 5 and 10 mg isradipine MR once daily has been shown to reduce the average 24 h blood pressure by 11 +/- 1/6 +/- 1 mm Hg (P less than .001) and 13 +/- 2/9 +/- 1 mm Hg (P less than .001), respectively, compared with placebo. There was no loss of efficacy with isradipine MR during the 24 h observation period with either dose. In conclusion, low-dose isradipine MR once daily is an effective first-line treatment in essential hypertension.

• Authors: W L Diemont, C J Stegeman, J Beekman, A M Siegers, G Hagels, J H de Bruijn
• Journal: American journal of hypertension (Am J Hypertens) Vol. 4 Issue 2 Pt 2 Pg. 163S-167S (Feb 1991) ISSN: 0895-7061 [Print] United States
• PMID: 1827011 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Antihypertensive Agents
• Delayed-Action Preparations
• Pyridines
• Isradipine

Topics

• Antihypertensive Agents (administration & dosage, therapeutic use)
• Blood Pressure (drug effects)
• Circadian Rhythm
• Delayed-Action Preparations
• Dose-Response Relationship, Drug
• Female
• Humans
• Hypertension (drug therapy, physiopathology)
• Isradipine
• Male
• Middle Aged
• Pyridines (administration & dosage, therapeutic use)